IL-2 and TCR stimulation induce expression and secretion of IL-32β by human T cells

Front Immunol. 2024 Aug 15:15:1437224. doi: 10.3389/fimmu.2024.1437224. eCollection 2024.

Abstract

IL-32 expression is important for pathogen clearance but detrimental in chronic inflammation, autoimmunity, and cancer. T cells are major IL-32 producers in these diseases and key mediators of pathogen and tumor elimination but also autoimmune destruction. However, their contribution to IL-32 biology during immune responses is hardly understood due to several isoforms with divergent inflammatory properties. Here, we identified IL-32β as the predominant isoform in various T cell subsets of healthy individuals and breast cancer patients with the highest levels detected in intratumoral regulatory T cells. We show that IL-32β is induced by IL-2 but IL-32β release requires T Cell Receptor rather than IL2R stimulation. Using inhibitors of protein secretion pathways and serial (ultra)centrifugation of T cell supernatants, we demonstrate that T cells actively secrete IL-32β unconventionally, as a free protein and, to a minor degree, through exosomes. Thus, our data identify activated T cells as major IL-32β secretors in health and cancer.

Keywords: IL-2; IL-32 isoform; IL-32 secretion mechanism; IL-32β; T cells; cancer; exosomes; unconventional secretion pathway.

MeSH terms

  • Breast Neoplasms* / immunology
  • Breast Neoplasms* / metabolism
  • Female
  • Humans
  • Interleukin-2* / metabolism
  • Interleukins* / metabolism
  • Lymphocyte Activation* / immunology
  • Receptors, Antigen, T-Cell* / immunology
  • Receptors, Antigen, T-Cell* / metabolism
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism

Substances

  • Interleukins
  • IL32 protein, human
  • Interleukin-2
  • Receptors, Antigen, T-Cell

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. FS was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Collaborative Research Program (Forschungsgruppe 2858; Project Number: 422166657). MX is supported by the “SATURN3 - Spatial And Temporal Resolution of Intratumoral Heterogeneity in 3 hard-to-treat CaNcers” in the BMBF funding line joint research on “Tumor Heterogeneity, Clonal Tumor Evolution and Therapy Resistance”. AWö and NK were funded by the Bavarian Cancer Research Center (BZKF).